RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+2.78%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.04B
AUM Growth
+$1.04B
(-1.3%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
1.09%
Top 10 Holdings %
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5
Top Buys
| 1 |
UnitedHealth
UNH
|
$33M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$10.5M |
| 3 |
Danaher
DHR
|
$9.37M |
| 4 |
Edwards Lifesciences
EW
|
$9.01M |
| 5 |
Elevance Health
ELV
|
$8.83M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$20.8M |
| 2 |
Cigna
CI
|
$20.8M |
| 3 |
Tenet Healthcare
THC
|
$20.1M |
| 4 |
Medtronic
MDT
|
$9.21M |
| 5 |
Natera
NTRA
|
$8.99M |
Sector Composition
| 1 | Healthcare | 99.92% |
| 2 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Viking Therapeutics
VKTX
$3.02B
| $6.1M | 0.59% |
115,000
-30,000
| -21% | -$1.59M |
|
52
Glaukos
GKOS
$5.42B
| $5.92M | 0.57% |
50,000
+23,000
| +85% | +$2.72M |
|
53
Merus
MRUS
$5.04B
| $5.35M | 0.51% |
+90,500
| New | +$5.35M |
|
54
Encompass Health
EHC
$12.5B
| $5.15M | 0.49% |
60,000
+31,000
| +107% | +$2.66M |
|
55
Syndax Pharmaceuticals
SNDX
$1.39B
| $4.69M | 0.45% |
228,500
+50,000
| +28% | +$1.03M |
|
56
BridgeBio Pharma
BBIO
$9.91B
| $4.67M | 0.45% |
184,500
+80,000
| +77% | +$2.03M |
|
57
Mirum Pharmaceuticals
MIRM
$3.75B
| $4.59M | 0.44% |
134,250
+42,000
| +46% | +$1.44M |
|
58
Janux Therapeutics
JANX
$1.38B
| $4.48M | 0.43% |
106,847
+2,347
| +2% | +$98.3K |
|
59
Annexon
ANNX
$225M
| $4.41M | 0.42% |
+900,000
| New | +$4.41M |
|
60
Esperion Therapeutics
ESPR
$490M
| $4.38M | 0.42% |
+1,975,000
| New | +$4.38M |
|
61
ESSA Pharma
EPIX
$11.2M
| $4.24M | 0.41% |
806,054
-105,766
| -12% | -$556K |
|
62
Xencor
XNCR
$594M
| $4.14M | 0.4% |
218,750
| – | – |
|
63
Penumbra
PEN
$10.5B
| $4.14M | 0.4% |
23,000
-23,000
| -50% | -$4.14M |
|
64
TG Therapeutics
TGTX
$5.03B
| $3.8M | 0.36% |
213,500
+90,000
| +73% | +$1.6M |
|
65
Nurix Therapeutics
NRIX
$723M
| $3.64M | 0.35% |
+174,393
| New | +$3.64M |
|
66
Alkermes
ALKS
$4.95B
| $3.62M | 0.35% |
150,000
+40,000
| +36% | +$964K |
|
67
Krystal Biotech
KRYS
$4.35B
| $3.49M | 0.34% |
19,000
| – | – |
|
68
Immunovant
IMVT
$2.91B
| $3.45M | 0.33% |
130,500
+5,000
| +4% | +$132K |
|
69
Kura Oncology
KURA
$732M
| $3.43M | 0.33% |
166,526
| – | – |
|
70
STAAR Surgical
STAA
$1.35B
| $3.09M | 0.3% |
+65,000
| New | +$3.09M |
|
71
Acadia Healthcare
ACHC
$2.15B
| $2.69M | 0.26% |
39,824
+27,200
| +215% | +$1.84M |
|
72
Inspire Medical Systems
INSP
$2.53B
| $2.28M | 0.22% |
17,000
-25,000
| -60% | -$3.35M |
|
73
Apellis Pharmaceuticals
APLS
$3.51B
| $2.12M | 0.2% |
55,395
-123,000
| -69% | -$4.72M |
|
74
Molina Healthcare
MOH
$9.6B
| $2.08M | 0.2% |
+7,000
| New | +$2.08M |
|
75
Transmedics
TMDX
$3.65B
| $2.03M | 0.2% |
+13,500
| New | +$2.03M |
|